1 Department of Intensive Care Medicine and.
3 Pharmacy Department, Royal Brisbane and Women's Hospital, Brisbane, Australia.
Am J Respir Crit Care Med. 2016 Sep 15;194(6):681-91. doi: 10.1164/rccm.201601-0024OC.
Optimization of β-lactam antibiotic dosing for critically ill patients is an intervention that may improve outcomes in severe sepsis.
In this individual patient data meta-analysis of critically ill patients with severe sepsis, we aimed to compare clinical outcomes of those treated with continuous versus intermittent infusion of β-lactam antibiotics.
We identified relevant randomized controlled trials comparing continuous versus intermittent infusion of β-lactam antibiotics in critically ill patients with severe sepsis. We assessed the quality of the studies according to four criteria. We combined individual patient data from studies and assessed data integrity for common baseline demographics and study endpoints, including hospital mortality censored at 30 days and clinical cure. We then determined the pooled estimates of effect and investigated factors associated with hospital mortality in multivariable analysis.
We identified three randomized controlled trials in which researchers recruited a total of 632 patients with severe sepsis. The two groups were well balanced in terms of age, sex, and illness severity. The rates of hospital mortality and clinical cure for the continuous versus intermittent infusion groups were 19.6% versus 26.3% (relative risk, 0.74; 95% confidence interval, 0.56-1.00; P = 0.045) and 55.4% versus 46.3% (relative risk, 1.20; 95% confidence interval, 1.03-1.40; P = 0.021), respectively. In a multivariable model, intermittent β-lactam administration, higher Acute Physiology and Chronic Health Evaluation II score, use of renal replacement therapy, and infection by nonfermenting gram-negative bacilli were significantly associated with hospital mortality. Continuous β-lactam administration was not independently associated with clinical cure.
Compared with intermittent dosing, administration of β-lactam antibiotics by continuous infusion in critically ill patients with severe sepsis is associated with decreased hospital mortality.
优化β-内酰胺类抗生素在危重症患者中的剂量是一项干预措施,可能改善严重脓毒症患者的预后。
在这项对患有严重脓毒症的危重症患者进行的个体患者数据荟萃分析中,我们旨在比较连续输注和间歇性输注β-内酰胺类抗生素治疗的临床结局。
我们确定了比较严重脓毒症危重症患者连续输注与间歇性输注β-内酰胺类抗生素的相关随机对照试验。我们根据四项标准评估研究质量。我们合并了来自研究的个体患者数据,并评估了常见基线人口统计学和研究终点的数据完整性,包括以 30 天为截止日期的住院死亡率和临床治愈率。然后,我们确定了汇总的效应估计值,并在多变量分析中调查了与住院死亡率相关的因素。
我们确定了三项随机对照试验,研究人员共招募了 632 名患有严重脓毒症的患者。两组在年龄、性别和疾病严重程度方面平衡良好。连续输注组和间歇性输注组的住院死亡率和临床治愈率分别为 19.6%和 26.3%(相对风险,0.74;95%置信区间,0.56-1.00;P=0.045)和 55.4%和 46.3%(相对风险,1.20;95%置信区间,1.03-1.40;P=0.021)。在多变量模型中,间歇性β-内酰胺给药、更高的急性生理学和慢性健康评估 II 评分、使用肾脏替代治疗和感染非发酵革兰阴性杆菌与住院死亡率显著相关。连续β-内酰胺给药与临床治愈率无独立相关性。
与间歇性给药相比,严重脓毒症危重症患者连续输注β-内酰胺类抗生素与降低住院死亡率相关。